Genmab — Maj 2017
-
God morgen.
-
Nu kender jeg godt nok ikke så meget til Vestas aktien - men vil ikke være overrasket hvis det er fordi der er langt mere kurs spekulation omkring Genmab.
-
Det virker i hvert fald til at der nogle store fætre som forsøger at kontrollere hvordan genmab går op og ned.
-
ADCT-301 nu også på 4 hospitaler i England (NHL): https://clinicaltrials.gov/ct2/show?term=adct-301&rank=2
-
http://medwatch.dk/Medicinal___Biotek/article9561260.ece?utm_campaign=Middag&utm_content=2017-05-08 12%3A15%3A23&utm_medium=top&utm_source=Feed . Seattle genentics dropper mia. Aftale med immunomedics. Så må de kunne koncentrere sig om Genmab.
-
https://globenewswire.com/news-release/2017/05/08/979991/0/en/Horizon-Pharma-plc-Announces-Agreement-to-Acquire-River-Vision-Development-Corp-and-Teprotumumab-RV001-a-Biologic-in-Late-Stage-Development-for-Rare-Eye-Disease.html de var hurtige med købsknappen efter ph2 - DB fik hurtigt opsnappet nyheden.
-
Horizon anticipates a potential peak annual sales opportunity for teprotumumab, if approved, in excess of $250 million in the United States.
-
Så med 5% royalties til Genmab fra år 2022, vil det give 12,5 mio. USD til Genmab i årligt peak sales. Hmmm nok ikke det der kommer til at rykke kursen.
-
Royaltyprocent og årstal er rent gætteri fra min side! Kan måske være bedre?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind